Plasma Biomarkers of Muscle Metabolism During Exercise to the Assessment of Insulin Resistance in CKD Dialysis Patients
NCT ID: NCT06360302
Last Updated: 2024-11-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
42 participants
INTERVENTIONAL
2024-11-18
2026-11-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The hypothesis is that the addition of plasma metabolic intermediates associated with energy disorders linked to insulin resistance, will improve the sensitivity of the assessment of muscle oxidative metabolism abnormalities, as reported in exercise intolerant subjects.
In this way, the metabolomics approach during exercise would provide a biological and functional "signature" of insulin resistance of muscular origin, discriminating between insulin-resistant patients, healthy control subjects and dialysis patients, with an exercise metabolic profile approaching that observed in insulin-resistant patients. A better understanding of metabolic abnormalities could guide muscle rehabilitation.
Participants will be asked to perform an exercise test, with several blood samples taken at different exercise intensities.
Researchers will compare the metabolic profile of three groups: patients with chronic kidney disease, patients with metabolic syndrome and healthy subjects:
* V'O2-adjusted lactate at rest and during exercise
* The combination of exercise energy metabolism intermediates reflecting insulin resistance among Krebs cycle cofactors/substrates, ß-oxidation cofactors/substrates, amino acids
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of Professional Practices in Muscle Rehabilitation of Chronic Hemodialysis
NCT04820140
Effect of Intradialytic Exercises in Chronic Kidney Disease Patients
NCT06293092
Oxidative Stress on Muscle Dysfunction in Hemodialysis Patient
NCT02794142
Intradialysis Exercise Functional Capacity, Body Composition and Survival in Hemodialysis Patients
NCT06788054
Intradialytic Progressive Resistance Training for Maintenance Haemodialysis Patients
NCT01007838
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Metabolic impairments are numerous and complex: dyslipidemia, phospho-calcium disorders, hormonal and nutritional disturbances.
In these patients, the onset of insulin resistance is virtually systematic, but its assessment remains a challenge. In fact, the classic screening method known as HOMA-IR, using simultaneous measurement of insulin and plasma glucose levels, is greatly affected by dialysis and the timing of its implementation. The reference method known as the hyperinsulinemic-euglycemic clamp is difficult to perform in HD patients.
While insulin resistance is a condition that can be reversed by physical activity in chronic pathologies, the absence of a validated assessment method for CKD in HD represents a missed opportunity for prevention in CKD, at a time when muscle rehabilitation programs are developing in CKD.
Moreover, insulin resistance is associated with skeletal striated muscle dysfunction in CKD patients, and constitutes another major comorbidity in these patients, as skeletal striated muscle is the main tissue utilizing glucose in response to insulin. The research team has shown that muscular dysfunctions associating reduced muscle strength and/or muscular atrophy are a morbi-mortality factor in dialysis patients. Finally, molecular abnormalities associate a switch of muscle fibers towards glycolytic fibers and mitochondrial abnormalities strongly suggesting an energy dysfunction.
In a preliminary study, the research team were able to demonstrate in dialysis patients an alteration in energy metabolism, comparable to a loss of "metabolic flexibility", mimicking that observed in insulin-resistant patients without renal dysfunction. A better understanding of the components of energy anomalies and insulin resistance could guide muscle rehabilitation protocols and prevent complications associated with insulin resistance.
Currently, the only valid, non-invasive method used in clinical practice to demonstrate impairment of muscular oxidative metabolism is the measurement of carbohydrate/lipid utilization rate during an exercise test. This "metabolic stress test" makes it possible to determine the point of maximum lipid utilization (LIPOXMAX), the current reference marker of muscle metabolism during exercise.
Nevertheless, LIPOXMAX alone cannot provide an understanding of underlying metabolic abnormalities in energy pathways, and the assay of different muscle metabolites released into plasma during exercise (and their combination) has recently emerged as a specific and early assessment of insulin resistance.
In particular, parameters such as lactate or pyruvate measured in plasma at rest have been positively correlated with the HOMA-IR index and associated with an increased risk of developing type 2 diabetes. During exercise (metabolic stress test), lactate levels in insulin-resistant patients differ from those in healthy controls.
In view of the abnormalities of oxidative muscle metabolism in CKD and insulin-resistant patients, the measurement of lactate at rest and during exercise, adjusted for V'O2, could reveal a profile enabling discrimination of CKD and insulin-resistant patients from healthy control subjects.
With the addition of plasma metabolic intermediates associated with energy disorders linked to insulin resistance, The investigators hypothesize that their measurement during exercise will improve the sensitivity of the assessment of muscle oxidative metabolism abnormalities, as reported in exercise-intolerant subjects.
The metabolomics approach during exercise would provide a biological and functional "signature" of muscle-induced insulin resistance in haemodialysis patients. A better understanding of metabolic abnormalities could guide muscle rehabilitation.
This prospective, cross-sectional, repeated-measures comparative study comparing functional and biochemical response profiles to exercise between 2 groups of chronically ill patients and a group of healthy subjects.
This comparison of the metabolisms of the 3 groups is analyzed using repeated plasma sampling at different effort intensities.
* Plasma lactate adjusted to V'O2 (ratio) at rest and during exercise.
* V'O2-adjusted metabolic profile at rest and during exercise through a combination of exercise energy metabolism intermediates based on candidate metabolites with a significant correlation coefficient \>0.7 compared to LIPOXmax and/or HOMA-IR, among the following:
* Krebs cycle cofactors/substrates (lactate, pyruvate, malate, citrate, succinate, fumarate and alpha-cetoglutarate)
* ß-oxidation cofactors/substrates (free fatty acids, acyl-carnitine profile, beta-hydroxybutyrate, acetoacetate)
* Amino acid profile
* Acyl carnitine profile
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy volunters
Voluntary participants with no chronic diseases aged 40 to 75 wishing to take part in the study and benefit from an exercise test.
Exercise test
"Metabolic" effort test on cycloergometer with gas measurement. Gas exchanges (V'O2 and V'CO2) will be measured cycle-by-cycle using a gas analyzer connected to a flow meter Measurements will be taken every 6 minutes, at rest and during exercise on a cycloergometer, in five 6-minute increments, corresponding to intensities of 0% (rest), 20%, 30%, 40%, 50 and 60% of the subject's estimated maximum power, for a total duration of around 45 minutes.
Blood sample
A catheter will be placed in a forearm vein to take blood samples at rest and at the end of the 5-stage stress test.
Sampling times synchronized with stress test measurements
Impedancemetry
measurement of anthropometric data (weight, height, waist circumference). impedancemetry will enable body composition to be analyzed by placing surface electrodes on the body. The participant will lie on an examination table and must remain at rest for 5 minutes.
Metabolic syndrome patients
Patients aged 40 to 75 with metabolic syndrome undergoing functional assessment in the physiology department.
Exercise test
"Metabolic" effort test on cycloergometer with gas measurement. Gas exchanges (V'O2 and V'CO2) will be measured cycle-by-cycle using a gas analyzer connected to a flow meter Measurements will be taken every 6 minutes, at rest and during exercise on a cycloergometer, in five 6-minute increments, corresponding to intensities of 0% (rest), 20%, 30%, 40%, 50 and 60% of the subject's estimated maximum power, for a total duration of around 45 minutes.
Blood sample
A catheter will be placed in a forearm vein to take blood samples at rest and at the end of the 5-stage stress test.
Sampling times synchronized with stress test measurements
Impedancemetry
measurement of anthropometric data (weight, height, waist circumference). impedancemetry will enable body composition to be analyzed by placing surface electrodes on the body. The participant will lie on an examination table and must remain at rest for 5 minutes.
CKD dialysis patients
Chronic renal failure patients on dialysis, stable hemodialysis for more than 3 months
Exercise test
"Metabolic" effort test on cycloergometer with gas measurement. Gas exchanges (V'O2 and V'CO2) will be measured cycle-by-cycle using a gas analyzer connected to a flow meter Measurements will be taken every 6 minutes, at rest and during exercise on a cycloergometer, in five 6-minute increments, corresponding to intensities of 0% (rest), 20%, 30%, 40%, 50 and 60% of the subject's estimated maximum power, for a total duration of around 45 minutes.
Blood sample
A catheter will be placed in a forearm vein to take blood samples at rest and at the end of the 5-stage stress test.
Sampling times synchronized with stress test measurements
Impedancemetry
measurement of anthropometric data (weight, height, waist circumference). impedancemetry will enable body composition to be analyzed by placing surface electrodes on the body. The participant will lie on an examination table and must remain at rest for 5 minutes.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Exercise test
"Metabolic" effort test on cycloergometer with gas measurement. Gas exchanges (V'O2 and V'CO2) will be measured cycle-by-cycle using a gas analyzer connected to a flow meter Measurements will be taken every 6 minutes, at rest and during exercise on a cycloergometer, in five 6-minute increments, corresponding to intensities of 0% (rest), 20%, 30%, 40%, 50 and 60% of the subject's estimated maximum power, for a total duration of around 45 minutes.
Blood sample
A catheter will be placed in a forearm vein to take blood samples at rest and at the end of the 5-stage stress test.
Sampling times synchronized with stress test measurements
Impedancemetry
measurement of anthropometric data (weight, height, waist circumference). impedancemetry will enable body composition to be analyzed by placing surface electrodes on the body. The participant will lie on an examination table and must remain at rest for 5 minutes.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Postmenopausal women aged 40 to 75 or men aged 40 to 75
* No chronic disease or treatment
* BMI \<30 kg/m², or
* Fasting blood glucose \< 1.10 g/dL
Group 2: metabolic syndrome patients
* Postmenopausal women aged 40 to 75 or men aged 40 to 75
* Metabolic syndrome as defined by the International Diabetes Federation (IDF 2006)5
* BMI \<30 kg/m² and waist circumference \>80 cm for women and \>94 cm for men
* Insulin resistance defined by HOMA-IR\>2.4
Group 3: CKD dialysis patients
* Non-diabetics
* Postmenopausal women aged 40 to 75 and men aged 40 to 75
* BMI \<30 kg/m².
* Chronic kidney disease patients on dialysis - stable on HD for more than 3 months
Patients and healthy subjects will be matched on age (+/-3 years) and sex
Exclusion Criteria
* Ongoing exercise retraining program
* Nutritional supplementation in the 4 weeks preceding the study (antioxidants, vitamins, etc.)
* Treatment influencing mitochondrial function (metformin, statin, etc.)
* Failure to obtain written informed consent after a period of reflection
* Subject not affiliated to a social security scheme, or not benefiting from such a scheme.
* Person protected by law (under guardianship or curatorship)
* Patient deprived of liberty
* Diabetic patient
* Family dyslipidemia
* Participants who have reached the maximum amount of compensation for their participation in research projects
* Person under psychiatric care
* Person participating in another research project with an exclusion period still in progress.
* Mentally handicapped, dementia, illiterate, language barrier with inability to understand study purpose and methodology
40 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Montpellier
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GRILLET Pierre-Edouard, Pharma D. PhD
Role: STUDY_DIRECTOR
University Hospital, Montpellier
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AIDER Santé Fondation Charles Mion Montpellier, site Lapeyronie
Montpellier, , France
Montpellier University Hospital
Montpellier, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
FARES GOUZI, MD PhD
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Farès GOUZI
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RECHMPL22_0505
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.